Press release
Acinetobacter Pneumonia Therapeutics Market Forecast to Cross USD 927.1 Million by 2031 Amid Demand for Novel Antibiotics
Acinetobacter Pneumonia Therapeutics Market
The global Acinetobacter Pneumonia Therapeutics Market is estimated to reach over USD 927.1 Mn by 2031, exhibiting a CAGR of 5.30% during the forecast period.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2314
The Acinetobacter Pneumonia Therapeutics Market is undergoing notable expansion, driven by the rising global incidence of infections caused by Acinetobacter baumannii. This pathogen, known for its high level of resistance to multiple antibiotics, poses a significant challenge to respiratory health and underscores the urgent need for novel and effective treatment solutions. Current therapeutic approaches primarily involve the use of antibiotics such as carbapenems, cephalosporins, aminoglycosides, and polymyxins; however, the growing prevalence of multidrug-resistant strains continues to hinder treatment efficacy.
In parallel with therapeutic developments, diagnostic technologies that facilitate the timely detection and monitoring of Acinetobacter infections are gaining prominence, playing a critical role in patient management and infection control. Geographically, market growth is particularly evident in regions experiencing elevated infection rates.
Pharmaceutical manufacturers, diagnostic companies, and academic research institutions are actively investing in the development of innovative therapies and diagnostic tools. These collaborative research and development efforts are focused on overcoming antimicrobial resistance and improving clinical outcomes for patients affected by Acinetobacter pneumonia.
List of Prominent Players in the Acinetobacter Pneumonia Therapeutics Market:
• Pfizer Inc.
• Merck & Co., Inc.
• GlaxoSmithKline plc (GSK)
• AstraZeneca plc
• Novartis AG
• Johnson & Johnson
• Sanofi S.A.
• Bayer AG
• Basilea Pharmaceutica
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02
Market Dynamics
Drivers:
The growth of the Acinetobacter pneumonia therapeutics market is largely driven by intensified research and development initiatives aimed at addressing the increasing prevalence of multidrug-resistant Acinetobacter infections. This pathogen remains a significant cause of hospital-acquired morbidity and mortality globally, yet there are currently no approved vaccines or antiviral therapies specifically targeting the condition. The rising incidence of antibiotic resistance has created an urgent need for innovative treatment solutions. In response, pharmaceutical and biotechnology companies are expanding their research pipelines to develop effective therapeutic agents.
Additionally, the growing economic burden associated with treating Acinetobacter pneumonia is further fueling market growth. The World Health Organization has reported a more than 15% rise in healthcare-associated pneumonia caused by antibiotic-resistant Acinetobacter between 2015 and 2020. This trend has contributed to escalating healthcare expenditures, as treatment becomes increasingly complex and resource-intensive due to limited therapeutic options and resistance-related complications.
Challenges:
The Acinetobacter pneumonia therapeutics market faces several obstacles that may hinder its expansion. Chief among these are regulatory complexities that can delay product approvals and slow the integration of new therapies into existing healthcare systems. Securing regulatory clearance requires navigating rigorous clinical and administrative processes, which may extend development timelines. Intellectual property issues, including patent disputes and licensing constraints, further complicate market entry and commercialization efforts. Additionally, the presence of well-established market participants creates a competitive landscape in which new entrants must develop robust differentiation and marketing strategies to gain traction among healthcare providers and patients.
Regional Trends:
North America is expected to maintain a dominant position in the global Acinetobacter pneumonia therapeutics market, supported by substantial investment in healthcare infrastructure and robust pharmaceutical research and development activities. Conversely, the Asia Pacific region is poised for the highest growth rate over the forecast period, driven by increasing healthcare expenditures, expanding access to medical services, and improvements in healthcare infrastructure across emerging economies. These developments are creating favorable conditions for the adoption of advanced therapeutic solutions throughout the region.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2314
Recent Developments:
• In May 2023, Acinetobacter baumannii-calcoaceticus complex-susceptible strains of bacteria caused hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). The U.S. Food and Drug Administration approved Xacduro (sulbactam for injection) as a novel treatment for patients 18 years of age and older.
• In April 2023, Innoviva, Inc. announced that the U.S. Food and Drug Administration's (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) unanimously voted 12-0 to approve sulbactam-sulbactam for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains.
• In January 2024, Sanofi declared its intent to purchase the American biotech company Inhibrx for a maximum of $2.2 billion. The company's INBRX-101, an investigational remedy for Alpha-1 Antitrypsin Deficiency (AATD), a hereditary, rare illness that results in progressive lung tissue degradation, is the main focus of the acquisition.
Segmentation of Acinetobacter Pneumonia Therapeutics Market-
By Drug Class -
• Cephalosporins
• Carbapenems
• Aminoglycosides
• Polymyxins
By Route of Administration-
• Oral
• Intravenous
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa
Read Overview Report- https://www.insightaceanalytic.com/report/acinetobacter-pneumonia-therapeutics-market/2314
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Acinetobacter Pneumonia Therapeutics Market Forecast to Cross USD 927.1 Million by 2031 Amid Demand for Novel Antibiotics here
News-ID: 4079239 • Views: …
More Releases from Insightace Analytic Pvt Ltd.
Vaccine Contract Manufacturing Market to Reach USD 3.9 Billion by 2034 Driven by …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Vaccine Contract Manufacturing Market - (By Vaccine Type (Attenuated, Inactivated, Subunit-based, Toxoid-based, DNA-based), By Type of Expression System (Avian Expression Systems, Bacterial Expression Systems, Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs), Insect Expression Systems, Mammalian Expression Systems, Plant Expression Systems, Yeast Expression Systems), By Workflow (Downstream, Upstream), By Application (Human Use, Veterinary)), Trends,…
Gemigliptin Market Current Scenario with Future Aspect Analysis
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global xx Market Size, Share & Trends Analysis Report By Type of Drug (Gemigliptin Monotherapy & Gemigliptin Combination Therapy), By Dosage Form (Gemigliptin Tablets & Gemigliptin Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, & Online Pharmacies), By End-User (Hospitals, Clinics and Outpatient Facilities, & Homecare Settings), By Patient Demographics (Adultand Geriatric), Region, Market Outlook And…
Cell Line Development Market Experiences Rapid Innovation as Biotech Firms Prior …
InsightAce Analytic Pvt. Ltd. Announces the release of a market assessment report on the "Cell Line Development Market"-, By Source of Cell Lines (Transgenic, Yeast, Bacteria, Mammalian Cells), By Application (Research and Development, Drug Development), By Company Size (Very Large and Large, Mid-sized, Small), By Biologics Type (Recombinant Proteins, Others), and Global Forecasts, 2025-2034 And Segment Revenue and Forecast To 2034."
The Cell Line Development Market is estimated to…
Breast Cancer Core Needle Biopsy Market Benefits from Increased Awareness and Ra …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Breast Cancer Core Needle Biopsy Market - (By Technology (MRI-based Breast Biopsy, Ultrasound-based Breast Biopsy, Mammography-based (Stereotactic) Breast Biopsy, CT-based Breast Biopsy, Other Image Based Breast Biopsy), By End-use (Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, Academic & Research Institutes)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by…
More Releases for Acinetobacter
Global Acinetobacter Infections Treatment Market Manufacturers, Type, Applicatio …
A recent report published by QY Research, titled, Acinetobacter Infections Treatment, provides an in-depth analysis of the global Acinetobacter Infections Treatment market. The research report is divided in a way to highlight the key areas of the market and provide a comprehensive understanding to the reader. The report deals with various aspects of the Acinetobacter Infections Treatment market such as its scope to studies its drivers and the restrains, market…
Global Acinetobacter Infections Treatment Market Research Report 2020
LOS ANGELES - USA, Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or "species" of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.
Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.
Acinetobacter is often resistant to many commonly…
United States Acinetobacter Infections Treatment Market Overview And Forecasts 2 …
Qyresearchreports include new market research report "United States Acinetobacter Infections Treatment Market Report 2018" to its huge collection of research reports.
The United States Acinetobacter Infections Treatment market has been meticulously researched on and studied and detailed on in this publication with the help of advanced primary and secondary research that has been performed by the best of analysts and using the best of the available techniques. The publications that enable…
Acinetobacter Infections Treatment Market Share and Forecasts Research Report 20 …
Acinetobacter Infections Treatment market get comprehensive research offering detailed regional analysis and growth outlook in a new report now available at MarketStudyReport.com
An inherent sub-vertical of the Healthcare industry space, Acinetobacter Infections Treatment Market stands to gain remarkable proceeds over 2018-2023, as per a recently compiled report. Covering the pivotal geographies of the Asia Pacific, Middle East and Africa (MEA), South America, North America, and Europe, this report minutely categorizes global…
Acinetobacter Infections Treatment Market with Worldwide Industry Analysis to 20 …
Global Acinetobacter Infections Treatment Market: Overview
Acinetobacter baumannii is a rod shaped gram-negative coccobacillus bacterium. This bacterium is becoming an important cause of hospital derived bacterial infection affecting people with weakened immune system. Acinetobacter infections usually affect organ systems, which have a high content of fluid (e.g. peritoneal fluid, respiratory tract, urinary tract, cerebrospinal fluid etc.) leading to infections related to continuous ambulatory peritoneal dialysis and nocosomial pneumonia. At present,…
Acinetobacter Infections - Pipeline Review, H1 2017 - Pharmaceutical Market Repo …
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acinetobacter Infections - Pipeline Review, H1 2017, provides an overview of the Acinetobacter Infections (Infectious Disease) pipeline landscape.
Acinetobacter is a gram-negative coccobacillus. Acinetobacter infections are uncommon but, when they occur, usually involve organ systems that have a high fluid content (respiratory tract, CSF, peritoneal fluid, urinary tract). Symptoms include fever (high body temperature), red, swollen, warm or painful skin areas…
